Oral GLP-1
5 articles on Oral GLP-1, written by Shotlee and medically reviewed for clinical accuracy.
Wegovy Pill Hits 26K Prescriptions in Week 2: Launch Breakdown
Novo Nordisk's new Wegovy pill has exploded onto the scene, racking up over 26,000 prescriptions in just its second full week. This needle-free GLP-1 option signals a shift in obesity treatment. Discover the data, science, and patient implications behind this rapid uptake.
4 min read
Novo Nordisk Pushes Consumer-Friendly Wegovy Pill
Novo Nordisk ramps up direct-to-consumer access to its new daily Wegovy pill through NovoCare's redesign and telehealth ties. Berenberg analysts see rising demand from consumers seeking speed and privacy over traditional clinics. This shift makes GLP-1 weight loss treatment feel like online shopping.
1 min read
Novo's Wegovy Oral Pill Shows Strong Early US Momentum vs Lilly
Novo Nordisk's new oral Wegovy pill achieved 3,071 retail prescriptions in its first four days in the US. This strong start signals competition with Eli Lilly's offerings. Analysts predict up to $1 billion in 2024 sales if momentum continues.
1 min read
5 Things to Know Before Switching to Oral GLP-1 Pills
Oral GLP-1 medications offer a convenient alternative to weekly injections for weight loss. Discover the main differences in absorption, dosing, and routine. Follow these 5 tips to ensure a successful switch without losing progress.
2 min read
Doctor Compares Wegovy Injections to New Weight Loss Pill
The new FDA-approved Wegovy pill offers the same weight loss benefits as injections but in a daily oral dose. Dr. Drew Payne explains why higher doses are needed due to GI absorption and how both achieve 15% average weight loss. Costs drop significantly, making treatment more affordable.
2 min read